Genmab — April 2019
-
While RTOR currently is being piloted for only the most straightforward supplemental applications, future expansion to more complex supplements or to NEW molecular entities (NME). Måske det, de har i tankerne med accellerated https://www.focr.org/news/pink-sheet-real-time-oncology-review-has-sponsors-rethinking-what-data-share-us-fda-and-when
-
Jeg har snakket med Genmab. Andrew afløser Jan som er forhindret i at deltage på dagen for Q&A.
-
Hvis Andrew får problemer med at svare på enkelte spørgsmål får vi svaret eftersendt.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind

